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Summary Survival and prognostic factors were analysed in 150 patients with histologically confirmed epithelial ovarian cancer stage IA-IIA.
The relapse-free and overall survival rates were, respectively, 81% and 88% after 3 and 74% and 84% after 5 years. The analysis of various
prognostic factors indicates as the main factor the grade differentiation of the tumour.
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Few studies have been conducted on prognostic factors in early-
stage (I-IIA) ovarian cancer. Some authors have suggested that
age, tumour grade, stage and rupture ofthe tumour capsule have a
relevant impact on the survival of early ovarian cancer patients
(Webb et al, 1973; Einhom et al, 1985). A recent study including
194 patients with stage I ovarian cancer identified grade, presence
of ascites and surface tumour as independent prognostic factors
(Ahmed et al, 1996). Other studies, however, did not confirm these
indications (Dembo et al, 1986, 1990). To provide furtherinforma-
tion, we considered the prognostic factors in a series of patients
with early ovarian cancer.
PATIENTS AND METHODS
Between 1981 and 1996, 150 consecutive patients with histologi-
cally confirmed epithelial ovarian cancer stage IA-IIA (median
age 53 years, range 23-76 years) were observed at the First
Obstetric and Gynecologic Clinic of the University of Milan. At
first diagnosis all patients underwent a total abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, omentectomy and at least
eight multiple biopsies plus washing ofthe abdominal cavity. The
patients with conservative surgery are notincluded in this analysis.
RESULTS
The patients' characteristics are shown in Table 1. Stage was IA in
51 cases, IB in ten cases, IC in 78 cases and IIA in 11 cases. After
surgery, 75 patients were treated with chemotherapeutic regimens
including cisplatinum alone or in combination with cyclophos-
phamide, 58 did not receive any treatment and in 17 patients treat-
ment with P32 was performed. All patients treated with adjuvant
chemotherapy were stage IA-IB G2-G3, or IC-IIA all grades.
Survival time was computed from the date of diagnosis until
date ofdeath (or ofclinical or pathological relapse for disease-free
survival) or censored to the last follow-up data. No patient was
lost to follow-up. At the cut-offdate, September 1996, the median
of follow-up was 70 months (range 9-181 months). Survival
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probabilities were estimated according to Kaplan-Meier and
compared using the log-rank test. The Cox model (Cox, 1972) was
fitted to the data after graphical check of proportional hazards
assumption to evaluate the prognostic value ofconsidered factors,
taking into account the potential reciprocal confounding effect.
At the time ofthe study analysis, 39 women had relapsed and 29
had died (27 out of the 39 who relapsed and 2 out of Ill with no
recurrence ofdisease for causes unrelated to ovarian cancer).
The relapse-free and overall survival rates were, respectively,
81% and 88% after 3 years and 74% and 84% after 5 years.
Patients 53 years old or less tended to have a better 5-year
survival rate (88%) than the older ones (79%; log-rank test P =
0.04, multivariate analysis P = 0.07).
Table 1 Patients' characteristics and survival according to various
prognostic factors. Milan, Italy, 1981-1996
Number Survival (%)
3 years 5 years
Total 150 88 (18) 84 (23)
Age (years)
< 53 77 91 (7)a 88 (9)
>53 73 84 (11) 79 (14)
Stage
IA-IB 61 91 (5) 91 (5)
IC 78 86 (11) 80 (15)
IIA 11 82 (2) 73 (3)
Histotype
Serous, mucinous, endometrioid, 120 92 (9)b 88 (13)
undifferentiated, clear cell 30 70 (9) 66 (10)
Grade
G1-G2 99 95 (5) 91 (8)c
G3 51 74 (13) 69 (15)
Tumour volume at first diagnosis (cm)
< 10 52 89 (5) 86 (7)
> 10< 20 75 85 (10) 79 (12)
>20 23 87 (3) 82 (4)
aMultivariate estimates including terms for age, stage, histotype and tumour
grade; P= 0.07. bMultivariate estimates including terms for age, stage,
histotype and tumour grade; P= 0.59. cMultivariate estimates including terms
for age, stage, histotype and tumour grade; P= 0.04.
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Women with clear-cell and undifferentiated tumour type had a 5-
year survival of 66% compared with 88% for women with other
histological types (log-rank test P = 0.002), but this difference was
not significant in the multivariate analysis (P =0.59). Tumourgrade
3 had a 69% 5-year survival rate, compared with 91% for grade 1-2
(log-rank test P = 0.0004; multivariate analysis, P = 0.04).
Compared with patients with stage IC, there was a significant
difference in survival after 5 years between women with presence
of tumour with or without ascites on the surface of the ovary
(88%) or intraoperative rupture ofthe tumour capsule (72%) (data
not shown in Table, multivariate analysis P = 0.03).
The site of relapse was the pelvis and/or the vaginal cuff in 16
(41%) cases and extrapelvic in 23 (59%) cases. No relationship
emerged between site of relapse and age, histotype, grade, stage
and tumour volume at first surgery.
Out of 39 patients with recurrent disease, 24 were treated with
chemotherapy alone, eight with chemotherapy plus surgery and/or
radiotherapy and three with radiotherapy alone; four patients had
no treatment. The response to treatment at relapse was 'complete'
in 11 patients (six out ofthe 16 patients with pelvic and/or vaginal
cuff relapse and five out of the 23 patients with extrapelvic
relapse), 'partial' in seven 'no change' in seven and ten cases
progressed. Patients with recurrent disease had a 47% 3-year
survival rate after relapse.
DISCUSSION
The results of this study show that the prognosis of patients with
early-stage ovarian cancer is favourable. This finding is consistent
with previous published studies that showed 5-year survival rates
raging from 75% to 90% (Webb et al, 1973; Einhorn et al, 1985;
Sevelda et al, 1989; Dembo et al, 1990; Lund & Williamson, 1991;
Shueler et al, 1993; Ahmed et al, 1996). The analysis of various
prognostic factors indicates as main factor the grade differentiation
of the tumour. This finding is consistent with the results of
previous studies (Webb et al, 1973; Sevelda et al, 1989; Ahmed et
al, 1996). Thus, tumour grading is the main factor in the identifica-
tion of patients with early ovarian cancer who could benefit from
adjuvant chemotherapy.
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